Tumor Biology

, Volume 37, Issue 7, pp 9899–9907 | Cite as

The cancer-retina antigen recoverin as a potential biomarker for renal tumors

  • Marina O. Golovastova
  • Larisa V. Tsoy
  • Anna V. Bocharnikova
  • Dmitry O. Korolev
  • Olga S. Gancharova
  • Ekaterina A. Alekseeva
  • Ekaterina B. Kuznetsova
  • Lyudmila V. Savvateeva
  • Elena E. Skorikova
  • Vladimir V. Strelnikov
  • Vladimir A. Varshavsky
  • Andrey Z. Vinarov
  • Vladimir N. Nikolenko
  • Peter V. Glybochko
  • Evgeni Yu. Zernii
  • Andrey A. ZamyatninJr.
  • Alexandr V. Bazhin
  • Pavel P. Philippov
Original Article


The renal cell carcinoma is the ninth most common cancer with an increasing occurrence and mortality. Recoverin is the first retina-specific photoreceptor protein that was shown to undergo aberrant expression, due to its promoter demethylation, as a cancer-retina antigen in a number of malignant tumors. In this work, we demonstrated that recoverin is indeed expressed in 68.4 % of patients with different subtypes of renal cell carcinoma, and this expression has tendency to correlate with tumor size. Interestingly, 91.7 % of patients with the benign renal tumor, oncocytoma, express recoverin as well in their tumor. Epigenetic analysis of the recoverin gene promoter revealed a stable mosaic methylation pattern with the predominance of the methylated state, with the exception of -80 and 56 CpG dinucleotides (CpGs). While the recoverin expression does not correlate withoverall survival of the tumor patients, the methylation of the recoverin gene promoter at -80 position is associated with better overall survival of the patients. This work is the first report pointing towards the association of overall survival of renal cell carcinoma (RCC) patients with promoter methylation of a cancer-retina antigen. Taken together, these data allow to consider recoverin as a potential therapeutic target and/or marker for renal tumors.


Recoverin Cancer-retina antigens Onconeural antigens DNA methylation Renal cancer 



autoantibodies against recoverin


cancer-testis (germline) antigens


CpG dinucleotides


paraneoplastic antigen


tumor antigen


transcription start site



We are indebted to Ms. E.V. Bragina for her help in the preparation of the manuscript. This work was supported in part by grant numbers 12-04-00922 and 15-04-05171 to PPPh, 14-04-32360 to LVS, 15-04-07963 to EYZ, and 16-54-53115 to AAZ from the Russian Foundation for Basic Research.

Compliance with ethical standards

All experiments reported in this study involving human subjects complied with the ethical standards of the committee responsible for human experimentation (institutional and national) and with the Helsinki Declaration of 1975 as revised in 2008 and approved by the Ethics Committee at Sechenov First Moscow State Medical University (N04-12) prior to this study.

Informed consent

Informed consent was obtained from all patients included in the study.

Conflicts of interest


Supplementary material

13277_2016_4885_MOESM1_ESM.doc (36 kb)
Supplementary Table 1 Bisulfite sequencing primers and their genomic locations, PCR conditions and amplicon lengths. (DOC 35 kb)
13277_2016_4885_MOESM2_ESM.doc (30 kb)
Supplementary Fig. 1 Schematic representation of the first exon and promoter region of the recoverin gene. (DOC 30 kb)


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Scherr AJ, Lima JP, Sasse EC, Lima CS, Sasse AD. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer. 2011;11:115.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Raman R, Vaena D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. Biomed Res Int. 2015;2015:367354.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Eichmüller SB, Bazhin AV. Onconeural versus paraneoplastic antigens? Curr Med Chem. 2007;14:2489–94.CrossRefPubMedGoogle Scholar
  6. 6.
    Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Kimmins S, Sassone-Corsi P. Chromatin remodelling and epigenetic features of germ cells. Nature. 2005;434:583–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: characterization of 9 complete genes. Int J Cancer. 2002;101:448–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Chiriva-Internati M, Pandey A, Saba R, Kim M, Saadeh C, Lukman T, et al. Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol. 2012;31:321–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Golovastova MO, Bazhin AV, Philippov PP. Cancer-retina antigens—a new group of tumor antigens. Biochemistry (Mosc). 2014;79:733–9.CrossRefGoogle Scholar
  11. 11.
    Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer. 2006;119:117–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Savchenko MS, Goncharskaia MA, Skorikova EE, Eichmuller SB, Kushlinsky NE, Bazhin AV, et al. Autoantibodies against the ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases. Oncol Lett. 2012;3:377–82.PubMedGoogle Scholar
  13. 13.
    Chen H, Werner S, Tao S, Zornig I, Brenner H. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014;346:178–87.CrossRefPubMedGoogle Scholar
  14. 14.
    Caserta S, Borger JG, Zamoyska R. Central and effector memory cd4 and cd8 t-cell responses to tumor-associated antigens. Crit Rev Immunol. 2012;32:97–126.CrossRefPubMedGoogle Scholar
  15. 15.
    Savvateeva LV, Schwartz AM, Gorshkova LB, Gorokhovets NV, Makarov VA, Reddy VP, et al. Prophylactic admission of an in vitro reconstructed complexes of human recombinant heat shock proteins and melanoma antigenic peptides activates anti-melanoma responses in mice. Curr Mol Med. 2015;15:462–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Bazhin AV, Schadendorf D, Willner N, De Smet C, Heinzelmann A, Tikhomirova NK, et al. Photoreceptor proteins as cancer-retina antigens. Int J Cancer. 2007;120:1268–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Dizhoor AM, Chen CK, Olshevskaya E, Sinelnikova VV, Phillipov P, Hurley JB. Role of the acylated amino terminus of recoverin in ca(2+)-dependent membrane interaction. Science. 1993;259:829–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Polans AS, Buczylko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol. 1991;112:981–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bazhin AV, Savchenko MS, Shifrina ON, Demoura SA, Chikina SY, Jaques G, et al. Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. Lung Cancer. 2004;44:193–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Philippov PP, Zernii EY: Recoverin. Encyclopedia of signaling molecules 2012:1623-1629.Google Scholar
  21. 21.
    Matsuo S, Ohguro H, Ohguro I, Nakazawa M. Clinicopathological roles of aberrantly expressed recoverin in malignant tumor cells. Ophthalmic Res. 2010;43:139–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Bazhin AV, De Smet C, Golovastova MO, Schmidt J, Philippov PP. Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells. Exp Dermatol. 2010;19:1023–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37:1469–89.CrossRefPubMedGoogle Scholar
  24. 24.
    Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537–44.PubMedGoogle Scholar
  25. 25.
    Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Leroy X, Zini L, Leteurtre E, Zerimech F, Porchet N, Aubert JP, et al. Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of muc1 between the two subtypes. Mod Pathol. 2002;15:1126–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol. 2002;10:332–8.PubMedGoogle Scholar
  28. 28.
    Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005;25:247–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Senin II, Zargarov AA, Alekseev AM, Gorodovikova EN, Lipkin VM, Philippov PP. N-myristoylation of recoverin enhances its efficiency as an inhibitor of rhodopsin kinase. FEBS Lett. 1995;376:87–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Senin II, Tikhomirova NK, Churumova VA, Grigoriev II, Kolpakova TA, Zinchenko DV, et al. Amino acid sequences of two immune-dominant epitopes of recoverin are involved in ca2+/recoverin-dependent inhibition of phosphorylation of rhodopsin. Biochemistry (Mosc). 2011;76:332–8.CrossRefGoogle Scholar
  31. 31.
    Kuznetsova EB, Kekeeva TV, Larin SS, Zemlyakova VV, Khomyakova AV, Babenko OV, et al. Methylation of the bin1 gene promoter cpg island associated with breast and prostate cancer. J Carcinog. 2007;6:9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Li LC, Dahiya R. Methprimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Bazhin AV, Dalke C, Willner N, Abschütz O, Wildberger HGH, Philippov PP, et al. Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer. 2009;124:140–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancer/testis antigens and urological malignancies. Nat Rev Urol. 2012;9:386–96.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of mage genes in renal cell carcinoma. Int J Mol Med. 1998;2:57–60.PubMedGoogle Scholar
  36. 36.
    Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, et al. Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res. 2008;68:8240–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Bazhin AV, Schadendorf D, Philippov PP, Eichmüller SB. Recoverin as a cancer-retina antigen. Cancer Immunol Immunother. 2007;56:110–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Li J, Huang Q, Zeng F, Li W, He Z, Chen W, et al. The prognostic value of global DNA hypomethylation in cancer: a meta-analysis. PLoS One. 2014;9:e106290.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Borresen-Dale AL, et al. Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients. Int J Cancer. 2014;134:2615–25.CrossRefPubMedGoogle Scholar
  40. 40.
    Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544–55.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer. 2014;14:54.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Cheng Y, Yan Z, Liu Y, Liang C, Xia H, Feng J, et al. Analysis of DNA methylation patterns associated with the gastric cancer genome. Oncol Lett. 2014;7:1021–6.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Eggers H, Steffens S, Grosshennig A, Becker JU, Hennenlotter J, Stenzl A, et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (hic1) cpg island methylation in renal cell carcinoma. Int J Oncol. 2012;40:1650–8.PubMedGoogle Scholar
  44. 44.
    Patricio P, Ramalho-Carvalho J, Costa-Pinheiro P, Almeida M, Barros-Silva JD, Vieira J, et al. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. J Cell Mol Med. 2013;17:1048–58.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Xiao W, Wang J, Li H, Guan W, Xia D, Yu G, et al. Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol. 2013;190:291–301.CrossRefPubMedGoogle Scholar
  46. 46.
    He W, Li X, Xu S, Ai J, Gong Y, Gregg JL, et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun. 2013;435:526–32.CrossRefPubMedGoogle Scholar
  47. 47.
    Selvakumar P, Owens TA, David JM, Petrelli NJ, Christensen BC, Lakshmikuttyamma A, et al. Epigenetic silencing of Na, K-ATPase beta 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma. Epigenetics. 2014;9:579–86.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Morrissey JJ, Mobley J, Song J, Vetter J, Luo J, Bhayani S, et al. Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. Urology. 2014;83:256–e259-214.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Marina O. Golovastova
    • 1
  • Larisa V. Tsoy
    • 2
  • Anna V. Bocharnikova
    • 3
  • Dmitry O. Korolev
    • 4
  • Olga S. Gancharova
    • 1
  • Ekaterina A. Alekseeva
    • 3
    • 5
  • Ekaterina B. Kuznetsova
    • 3
    • 5
  • Lyudmila V. Savvateeva
    • 3
  • Elena E. Skorikova
    • 1
  • Vladimir V. Strelnikov
    • 3
    • 5
    • 6
  • Vladimir A. Varshavsky
    • 2
  • Andrey Z. Vinarov
    • 4
  • Vladimir N. Nikolenko
    • 7
    • 8
  • Peter V. Glybochko
    • 4
  • Evgeni Yu. Zernii
    • 1
  • Andrey A. ZamyatninJr.
    • 1
    • 3
  • Alexandr V. Bazhin
    • 9
  • Pavel P. Philippov
    • 1
  1. 1.Department of Cell Signalling, Belozersky Institute of Physico-Chemical BiologyLomonosov Moscow State UniversityMoscowRussia
  2. 2.Anatomic Pathology DepartmentSechenov First Moscow State Medical UniversityMoscowRussia
  3. 3.Institute of Molecular MedicineSechenov First Moscow State Medical UniversityMoscowRussia
  4. 4.Institute of Uronephrology and Human Reproductive HealthSechenov First Moscow State Medical UniversityMoscowRussia
  5. 5.Research Centre for Medical GeneticsMoscowRussia
  6. 6.Medical Biology Faculty, Department of Molecular Genetics and CytogeneticsPirogov Russian National Research Medical UniversityMoscowRussia
  7. 7.Sechenov First Moscow State Medical UniversityMoscowRussia
  8. 8.Faculty of Basic MedicineLomonosov Moscow State UniversityMoscowRussia
  9. 9.Department of General, Visceral, and Transplant SurgeryLudwig-Maximilians-University MunichMunichGermany

Personalised recommendations